VANCOUVER, BC / ACCESSWIRE / April 7, 2014 – Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (OTC PINK: ATTBF) (CSE: ATT), a specialty biotechnology company focused on the North American cannabis market, today announced the retention of TDM Financial as its full service investor relations firm to provide online branding, marketing, outreach, and investor relations management services. TDM Finacial also owns and operates CannabisFN.com a leading financial network serving the medical marijuana (MMJ) and cannabis industries.
“We are pleased to engage the services of TDM Financial as we transparently build a diverse and balanced shareholder base,” said Michael Withrow, CEO of Abattis Bioceuticals Corp. “TDM Financial’s extensive network and IR management expertise will help us realize increased investor education and shareholder development through fully-compliant and high-quality coverage on major financial news portals as we embark upon an aggressive growth strategy.”
“We are excited to be working with an early pioneer and thoughtful leader in the cannabis industry,” said TDM Financial President Daniel Minton. “We look forward to communicating the company’s growth strategy to the investment community and building a stable, long-term shareholder base.”
ON BEHALF OF THE BOARD
For further information, contact the Company’s CEO, Michael Withrow at (778) 896-6536 or at email@example.com.
About TDM Financial
TDM Financial is a financial branding, marketing and IR management company operating dedicated financial networks covering new, emerging and established companies across many different industries. Its flagship property, SECFilings.com, is a leading destination for sophisticated investors looking to track and analyze regulatory filings with the SEC with over 600,000 registered members receiving real-time e-mail alerts on companies they follow. TDM Financial issues original coverage on its clients that is delivered to exclusive audiences and syndicated widely on leading industry specific and mainstream financial websites and online outlets.
Learn more at http://www.tdmfinancial.com/ or by calling (877) 225-0326.
About Abattis Bioceuticals Corp.
Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions by supplying and partnering with companies to employ its vertical cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The company also has an extensive pipeline of high-quality products and Intellectual Property for the rapidly expanding botanical drug market. We follow strict Standard Operating Protocols and adhere to the Law’s of Canada and Foreign Jurisdictions. For more information, visit the Company’s website at www.abattis.com.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.
SOURCE: Abattis Bioceuticals Corp.